Our team
Leadership Team
Peter Wilderotter
President and CEO
With over three decades of experience working in the nonprofit sector, Peter Wilderotter has leveraged his expertise to expand and advance the mission of several organizations.
Peter was appointed as the President and CEO of the Christopher & Dana Reeve Foundation in 2007 after revamping how the organization approached fundraising. Reporting to the Board of Directors, Peter is responsible for setting the overarching vision for the Reeve Foundation and rallying support for initiatives that speed the delivery of treatments for spinal cord injury.
Before locking arms with the Reeve Foundation, Peter was the Vice President of Development at WNYC Radio, America’s largest public radio station. Previously, Peter held leadership roles at Planned Parenthood Federation of America and the NAACP, and started his career at the American Cancer Society.
Maggie Goldberg
Chief Operating Officer
As Chief Operating Officer, Maggie oversees the day-to-day management of the Reeve Foundation. She works with staff across departments to achieve the organization’s strategic goals and provides the leadership, management, and vision necessary to ensure the effective growth of the organization. In addition, she oversees the Foundation’s national Paralysis Resource Center dedicated to improving the lives of individuals impacted by paralysis through grants, resources and information, peer mentoring and public policy.
A graduate of the University of Pennsylvania, Maggie joined the Reeve Foundation in 2000 after a career in Washington DC, working for Witeck Combs Communications, Feld Entertainment and U.S. Senator Arlen Specter. For 13 years, she oversaw communications for the Reeve Foundation before becoming Vice President of Policy and Programs in 2014 and COO in 2019.
Aimee Hunnewell
Chief Development Officer
As the Chief Development Officer, Aimee oversees donor relations and all of the Reeve Foundation's fundraising initiatives, including major gifts, corporate & foundation relations, Team Reeve, special events, direct mail and planned giving.
A graduate of Boston College, Aimee first joined the Reeve Foundation's predecessor organization, the American Paralysis Association (APA) in 1997. She worked in a number of roles including Director of Special Events, before becoming the organization's Vice President of Development in 2010.
Aimee took a hiatus from the Reeve Foundation for a few years, to work on several successful fundraising campaigns and initiatives for nationally known youth development organizations, including Boys & Girls Clubs of America, Classroom, Inc., and most recently Girl Scouts. She returned to the Reeve Foundation in 2019 in her new position as Chief Development Officer.
Michele Loiacono
Vice President, Operations
Michele has been with the Reeve Foundation since 2000, starting as an administrative assistant and growing into roles of greater responsibility. As Vice President of Operations, Michele cultivates employment engagement opportunities, manages benefits for staff members, acts as a bridge between the finance and development teams, and oversees all office operations.
Additionally, she works as a liaison for the Board of Directors to communicate recent Foundation happenings and updates. Knowing Christopher and Dana personally and seeing their passion for the mission has always been the driving force behind her dedication to the organization.
Ethan Perlstein
Chief Scientific Officer
In this role, Dr. Perlstein will manage the Reeve Foundation's basic and translational research portfolio and lead venture philanthropy investments in pursuit of the Foundation's ultimate goal, curing spinal cord injury. Ethan brings to the Foundation nearly two decades of experience in biomedical research and over five years in biotech company formation and executive leadership.
Ethan holds a doctorate in molecular and cell biology from Harvard University and was a Lewis-Sigler Fellow at Princeton University from 2007-2012. In 2014, Ethan founded Perlara PBC, the first biotech public benefit corporation with a legal mandate to co-develop drugs in collaboration with families and communities affected by genetic diseases. During that time, Ethan served as a member of the Medical and Scientific Advisory Board of Global Genes, the leading rare disease community-led advocacy organization. Prior to becoming a biotech entrepreneur, Ethan conducted and led cross-disciplinary academic research in genetics, cell biology, neuroscience, pharmacology, and drug discovery.